Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Natera said Friday that it is collaborating with oncology research firm Medica Scientia Innovation Research (MEDSIR) on the MiRaDoR breast cancer trial for hormone receptor-positive, HER2-negative breast cancer.

Contract research organization Inotiv said Thursday that it has partnered with Lithuanian multiomics data analysis firm Vugene on artificial intelligence-assisted drug discovery.

Pfizer and Dynamiker Biotechnology signed a strategic cooperation agreement on December 1, 2025.

Diagnostics firm TrilliumBio said Tuesday that it is collaborating with Oncobit to offer the Swiss company's uveal melanoma monitoring assay in the US.

Molecular diagnostics firm BillionToOne reported after the close of the market on Tuesday that its Q3 2025 revenues more than doubled year over year.

Pillar Biosciences and AstraZeneca said Monday that they are expanding their collaboration on liquid biopsy testing to include China.

Paradigm Health announced last Thursday that it acquired Flatiron Health's clinical research business, establishing a multiyear collaboration between the two companies.

Natera announced last Friday that it has acquired cancer diagnostic firm Foresight Diagnostics for $275 million upfront.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.